OR10AD1 Activators
Chemical activators of OR10AD1 function by modulating the intracellular levels of cyclic nucleotides, such as cAMP and cGMP, and influencing protein kinases that can phosphorylate and activate the olfactory receptor. Forskolin directly stimulates adenylyl cyclase, which catalyzes the conversion of ATP to cAMP. The resultant rise in cAMP levels activates protein kinase A (PKA), an enzyme that can phosphorylate OR10AD1, enhancing its capacity to bind odorant molecules. Similarly, Isoproterenol, a beta-adrenergic agonist, elevates cAMP levels, which in turn activate PKA. The phosphorylation by PKA primes OR10AD1 for activation. Additionally, IBMX and Rolipram both elevate cAMP by inhibiting different phosphodiesterases (PDEs), which are enzymes that break down cAMP. IBMX is a non-selective PDE inhibitor, while Rolipram specifically inhibits PDE4. The inhibition of these enzymes by IBMX and Rolipram prevents cAMP degradation, leading to an accumulation that activates PKA, with subsequent activation of OR10AD1.
Sildenafil, Vardenafil, and Tadalafil operate by inhibiting PDE5, an enzyme responsible for the breakdown of cGMP. Inhibition of PDE5 leads to increased levels of cGMP, which activates protein kinase G (PKG). PKG can then phosphorylate OR10AD1, resulting in its activation. Zaprinast also targets PDE5, producing a similar effect on cGMP and PKG, leading to the activation of OR10AD1. On the other hand, Cilostamide and Anagrelide selectively inhibit PDE3, which also results in elevated cAMP levels, and subsequent activation of PKA. PKA can phosphorylate OR10AD1, thus playing a role in its activation. Lastly, Genistein, a tyrosine kinase inhibitor, can influence the activation of OR10AD1 indirectly. By inhibiting tyrosine kinases that negatively regulate signal transduction pathways, Genistein may enhance the processes leading to OR10AD1 activation, although the precise mechanisms by which this occurs are less direct compared to the actions of cAMP and cGMP on their respective kinases.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol, a beta-adrenergic agonist, raises cAMP levels, activating PKA. The activation of PKA can lead to phosphorylation and hence activation of OR10AD1, increasing its sensitivity to specific odorant molecules. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, which increases cAMP by preventing its breakdown. Elevated cAMP levels can lead to activation of PKA, which may phosphorylate and thereby activate OR10AD1. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, can indirectly lead to the activation of OR10AD1 by inhibiting negative regulatory tyrosine kinases, thereby potentially enhancing signal transduction processes that activate OR10AD1. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterase type 5 (PDE5), which prevents the breakdown of cGMP. Elevated cGMP can activate protein kinase G (PKG), which may phosphorylate and activate OR10AD1, thus increasing its ability to detect odorants. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits phosphodiesterase 4 (PDE4), leading to an increase in cAMP levels. This rise in cAMP can activate PKA, which then has the potential to phosphorylate and activate OR10AD1, enhancing its odorant signal transduction. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide selectively inhibits PDE3, leading to an increase in cAMP levels. The increased cAMP activates PKA, which may phosphorylate OR10AD1, leading to its activation and enhanced odorant signaling. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil, a PDE5 inhibitor, prevents cGMP breakdown, leading to activation of PKG. Activated PKG can phosphorylate OR10AD1, resulting in its activation and potentially increasing its response to various odorants. | ||||||
Tadalafil | 171596-29-5 | sc-208412 | 50 mg | $180.00 | 13 | |
Tadalafil acts as a PDE5 inhibitor, increasing cGMP levels, which can lead to the activation of PKG. PKG may then phosphorylate and activate OR10AD1, thereby enhancing its olfactory signaling capabilities. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits PDE3, leading to an increase in cAMP levels. This elevation in cAMP activates PKA, which is known to phosphorylate various proteins, potentially including OR10AD1, thus activating it and enhancing its function in olfactory signaling pathways. | ||||||